| Literature DB >> 26110105 |
Yuta Onodera1, Takeshi Teramura1, Toshiyuki Takehara1, Kanae Shigi1, Kanji Fukuda1.
Abstract
Oxidative stress within the arthritis joint has been indicated to be involved in generating mediators for tissue degeneration and inflammation. COX-2 is a mediator in inflammatory action, pain and some catabolic reactions in inflamed tissues. Here, we demonstrated a direct relationship between oxidative stress and Cox-2 expression in the bovine synovial fibroblasts. Furthermore, we elucidated a novel mechanism, in which oxidative stress induced phosphorylation of MAPKs and NF-κB through TAK1 activation and resulted in increased Cox-2 and prostaglandin E2 expression. Finally, we demonstrated that ROS-induced Cox-2 expression was inhibited by supplementation of an antioxidant such as N-acetyl cysteamine and hyaluronic acid in vitro and in vivo. From these results, we conclude that oxidative stress is an important factor for generation of Cox-2 in synovial fibroblasts and thus its neutralization may be an effective strategy in palliative therapy for chronic joint diseases.Entities:
Keywords: COX, cyclooxygenase; Cox-2; HA, hyaluronic acid; NAC, N-acetyl cysteamine; OA model; OA, osteoarthritis; PGs, prostaglandins; RA, rheumatoid arthritis; ROS, reactive oxygen species; Reactive oxygen species; SFs, synovial fibroblast cells; Synovial tissues; TAK1
Year: 2015 PMID: 26110105 PMCID: PMC4476901 DOI: 10.1016/j.fob.2015.06.001
Source DB: PubMed Journal: FEBS Open Bio ISSN: 2211-5463 Impact factor: 2.693
Primer sequences used for qRT-PCR in the present study.
| Primer name | Primer sequence (5′–3′) |
|---|---|
| Cox-2 | F: ACAACAGAGTGTGTGATGTGC |
| R: TGCTGTACGTAGTCTTCAATCAC | |
| Gapdh | F: GTGAAGGTCGGAGTGAACG |
| R: TAAAAGCAGCCCTGGTGAC | |
Primary antibodies used in the WB experiments.
| Antibody | Company | Dilution | Specific band (kDa) |
|---|---|---|---|
| Phospho p38 (Thr180/Tyr182, #4511) | Cell Signaling Technology | 1/3000 in Immuno-enhancer | 38 |
| p38 (#9212) | Cell Signaling Technology | 1/5000 in Immuno-enhancer | 38 |
| Phospho Erk1/2 (Thr202/Tyr204, #9101) | Cell Signaling Technology | 1/3000 in Immuno-enhancer | 42/44 |
| Erk1/2 (#4695) | Cell Signaling Technology | 1/5000 in Immuno-enhancer | 42/44 |
| Phospho JNK1/2 (Thr183/Tyr185, #4668) | Cell Signaling Technology | 1/1000 in Immuno-enhancer | 46/54 |
| JNK1/2 (#9252) | Cell Signaling Technology | 1/1000 in Immuno-enhancer | 46/54 |
| COX-2 (#12282) | Cell Signaling Technology | 1/5000 in Immuno-enhancer | 74 |
| Phospho TAK1 (Thr184/187, #4531) | Cell Signaling Technology | 1/1000 in Immuno-enhancer | 82 |
| TAK1 (#4505) | Cell Signaling Technology | 1/1000 in Immuno-enhancer | 82 |
| I-kappa B alpha (sc-371) | Santa Cruz Biotechnology | 1/1000 in Immuno-enhancer | 35–41 |
| Gapdh (3C2) | Abnova | 1/10,000 in Immuno-enhancer | 38 |
Primary antibodies used in the immunohistochemistry.
| Antibody | Company | Dilution |
|---|---|---|
| DNP(ROIK04) | SHIMA Laboratories | 1/300 in 10% Block Ace/TBS-T |
| COX-2(#12282) | Cell Signaling Technology | 1/300 in 10% Block Ace/TBS-T |
| Phospho TAK1(#4531) | Cell Signaling Technology | 1/300 in 10% Block Ace/TBS-T |
Fig. 1H2O2 addition induced Cox-2 expression in SFs. (A) Estimation of intracellular ROS after H2O2 stimulation to the SFs by APF staining. (B) qPCR assay for Cox-2 mRNA expression after H2O2 treatment. (C) Cox-2 protein expression in the H2O2-treated SFs shown by WB. (D) Increasing of PGE2 expression by H2O2 stimulation in dose dependent manner was detected by ELISA assay.
Fig. 2H2O2 addition induced Cox-2 and PGE2 expression through phosphorylation of MAPKs and IkB in the SFs. (A) Detection of phosphorylated p38, JNK, Erk and IκB in the H2O2-treated SFs by WB. (B) qPCR assay for the Cox-2 expression in the SFs treated with H2O2 and MAPKs or NF-κB inhibitors. Y-axis shows relative expression values to the untreated control. (C) WB analysis for Cox-2 expressions in the SFs treated with H2O2 and MAPKs or NF-κB inhibitors. (D) ELISA assays for PGE2 expression in the SFs treated with H2O2 and MAPKs or NF-κB inhibitors. Y-axis shows staining intensity (absorbance) of each sample.
Fig. 3TAK1 is involved in H2O2 mediated activation of MAPKs and NF-κB signaling cascades. (A) WB analysis for the phosphorylated status of MAPKs and IκB in the cells treated with H2O2 and TAK1 inhibitor. (B) pPCR analysis for Cox-2 expression in the cells treated with H2O2 and TAK1 inhibitor. (C) WB analysis for Cox-2 expression after H2O2 stimulation and TAK1 inhibition. (D) ELISA analysis for PGE2 expression after H2O2 stimulation and TAK1 inhibition.
Fig. 4Antioxidants attenuate ROS-mediated Cox2 and PGE2 expressions. (A) Estimation of the intracellular ROS levels in the cells treated with 100 μM H2O2 and 100 μM NAC or 2 mg/ml HA. (B) qPCR analysis for Cox-2 expression in the SFs treated with H2O2 and 100 μM NAC or HA at 0.5, 1, 2 and 5 mg/ml. (C) WB showing suppression of TAK1 phosphorylation and Cox2 expression in the cells treated with NAC and HA. (D) ELISA assays for PGE2 expression in the SFs treated with 100 μM H2O2, 100 μM NAC and 2 mg/ml HA.
Fig. 5Intra-articular injection of HA attenuated ROS accumulation and Cox-2 expression in the surgical OA mice. (A) Triplicate sections with hematoxylin and eosin (HE) staining from sham, DMM, and DMM joint treated with HA. F: Femur, T: Tibia, Me: Meniscus, Syn: Synovia, M: Muscle. Scale bar = 200 μm. (B) Quantified expression of immunofluorescence for the DNP, phosphorylated TAK1 and Cox-2. Different characters mean significant differences between each group.